Skip to main content
. 2022 May 18;28(15):3367–3377. doi: 10.1158/1078-0432.CCR-21-3347

Figure 4.

Figure 4. Confirmation of the interaction of Aiolos and Ikaros with NuRD complex proteins in primary DLBCL tumor biopsies. A, Representative fields of FFPE tumor samples from patients with DLBCL were immunohistochemically stained with Dapi (blue), CD20 (green), Ikaros, Isotype and CHD4. Positive interactions are shown via PLA (red foci). B, Graphical representation of interactions formed as measured by PLA foci for Aiolos/Isotype, Aiolos/HDAC1, Ikaros/HDAC1, Aiolos/HDAC2 and Ikaros/HDAC2 in DLBCL tumors (n = 111). C, Representative fields of FFPE samples from a patient with relapsed/refractory DLBCL administered with 3 mg avadomide on an intermittent schedule. Screening and on-treatment (cycle 1 day 10) biopsies were obtained. Tissues were then subjected to FFPE PLA immunofluorescence for Aiolos/Ikaros in complex with HDAC1/2. Dapi (blue), CD20 (green), positive interactions are shown via PLA (red foci).

Confirmation of the interaction of Aiolos and Ikaros with NuRD complex proteins in primary DLBCL tumor biopsies. A, Representative fields of FFPE tumor samples from patients with DLBCL were immunohistochemically stained with Dapi (blue), CD20 (green), and Ikaros, Isotype and CHD4. Positive interactions are shown via PLA (red foci). B, Graphical representation of interactions formed as measured by PLA foci for Aiolos/Isotype, Aiolos/HDAC1, Ikaros/HDAC1, Aiolos/HDAC2, and Ikaros/HDAC2 in DLBCL tumors (n = 111). C, Representative fields of FFPE samples from a patient with relapsed/refractory DLBCL administered with 3 mg avadomide on an intermittent schedule. Screening and on-treatment (cycle 1 day 10) biopsies were obtained. Tissues were then subjected to FFPE PLA immunofluorescence for Aiolos/Ikaros in complex with HDAC1/2. Dapi (blue), CD20 (green), positive interactions are shown via PLA (red foci).